Researchers have observed coronary microvascular dysfunction in a good number of patients with psoriasis. This is despite the fact that most of them hadn’t presented with any symptoms of cardiovascular illness. For their study, the researchers recruited 503 individuals who had been diagnosed with psoriasis but had not been diagnosed with cardiovascular disease.
Prior research has demonstrated that individuals with severe psoriasis have heightened cardiovascular mortality and morbidity. Despite this, there’s been limited studies on the mechanisms underlying the heightened risk.
The researchers were focused on learning more about the link between psoriasis and heart disease, centering on coronary blood flow. They examined the coronary microvascular system and looked at the extent to which small blood vessels could expand to allow for the blood to flow without interruptions. This is referred to as coronary reserve flow.
Each of the participants was required to undergo a Doppler echocardiogram, which assesses coronary microcirculation. This led to the discovery that more than 30% of the patients had undiagnosed coronary microvascular dysfunction.
Based on these results, the researchers determined that while there was no link to diabetes, hyperlipidemia or tobacco use, systemic inflammation did a play a role in the development of coronary microvascular dysfunction. The researchers also observed that inflammation reduced the flow of blood, while also interfering with other bodily processes.
In their report, the researchers stated that there was increasing evidence of inflammatory illnesses such as psoriasis, rheumatoid arthritis, psoriatic arthritis and inflammatory bowel disease, with an increased prevalence of cardiovascular microvascular dysfunction, even when apparent cardiovascular illnesses were absent.
One of the study’s authors, Dr. Stefano Piaserico, stated that the primary takeaway from this research was that severe psoriasis was linked to a high prevalence of microvascular dysfunction, despite the absence of standard cardiovascular risk factors. Piaserico, an associate professor of dermatology at Italy’s University of Padua, added that significant predictors of decreased coronary flow reserve included the duration and severity of psoriasis as well as the presence of psoriatic arthritis. He noted that this discovery underscored the importance of considering factors related to psoriasis when evaluating cardiovascular risk in patients suffering from severe psoriasis.
The authors also noted in their report that while autoimmune disorders were risk factors for cardiovascular illnesses, the disorders didn’t lead to cardiovascular illnesses automatically. The researchers recommend regular checkups where an individual’s blood pressure is tested as well as their heart health markers.
The study’s findings were reported in the “Journal of Investigative Dermatology.”
Given the additional health risks that patients diagnosed with psoriasis face, such as heightened risk for heart disease, the innovative nanosized antibody therapies that companies such as Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are working on could be a lifesaver since they could keep psoriasis in check or even reverse it so that patients don’t get to a level of developing secondary complications linked to their psoriasis diagnosis.
NOTE TO INVESTORS: The latest news and updates relating to Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN